Erythema Toxicum Neonatorum in Newborns and the Development of Asthma

This study has been completed.
Sponsor:
Information provided by:
University of Rochester
ClinicalTrials.gov Identifier:
NCT00178152
First received: September 12, 2005
Last updated: May 11, 2011
Last verified: May 2011
  Purpose

Erythema Toxicum Neonatorum (ETN) is a common skin finding that affects healthy full-term babies. Several authors have commented on the possible relationship between ETN and the development of atopic conditions, such as atopic dermatitis or respiratory disease later in life. There is a paucity of research addressing this issue.


Condition
Asthma
Erythema Toxicum Neonatorum

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Retrospective
Official Title: The Implication of Erythema Toxicum Neonatorum in Newborns on the Development of Future Asthma

Resource links provided by NLM:


Further study details as provided by University of Rochester:

Enrollment: 334
Study Start Date: May 2005
Study Completion Date: November 2005
Primary Completion Date: November 2005 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   3 Years to 9 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Case studies will include subjects between the ages of 3-9 years who have had at least 2 asthma diagnoses within the last 2 years. Patients will be selected based upon their ICD9 codes for asthma. Control subjects will be age matched and without an asthma diagnosis.

Criteria

Inclusion Criteria:

  • Children between the ages of 3-9 years who have had at least 2 asthma diagnoses within the last 2 years.
  • Control subjects will be age matched and without an asthma diagnosis.

Exclusion Criteria:

  • Children without accessible medical records
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00178152

Locations
United States, New York
Department of Pediatrics, University of Rochester
Rochester, New York, United States, 14642
Sponsors and Collaborators
University of Rochester
Investigators
Principal Investigator: Jill S Halterman, MD, MPH University of Rochester
Study Chair: Ritu Pabby, MD West Penn Allegheny Health System
  More Information

No publications provided

Responsible Party: Jill S. Halterman, MD, MPH, University of Rochester
ClinicalTrials.gov Identifier: NCT00178152     History of Changes
Other Study ID Numbers: 11627
Study First Received: September 12, 2005
Last Updated: May 11, 2011
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Asthma
Erythema
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases
Skin Diseases

ClinicalTrials.gov processed this record on April 15, 2014